Tang Yin-Liang, Liu I-Ju, Li Pi-Chun, Chiu Chien-Yu, Lin Chun-Yu, Huang Chung-Hao, Chen Yen-Hsu, Fu Chi-Yu, Chao Day-Yu, King Chwan-Chuen, Wu Han-Chung
Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
Am J Trop Med Hyg. 2017 Oct;97(4):1049-1061. doi: 10.4269/ajtmh.17-0003. Epub 2017 Jul 27.
Dengue virus (DENV) circulates in tropical and subtropical areas around the world, where it causes high morbidity and mortality. There is no effective treatment of infection, with supportive care being the only option. Furthermore, early detection and diagnosis are important to facilitate clinical decisions. In this study, seven monoclonal antibodies (mAbs) recognizing nonstructural protein 1 (NS1) of DENV were generated by hybridoma techniques. These antibodies can be divided into two groups: serotype-specific (DB6-1, DB12-3, and DB38-1) and nonspecific (consisting of antibodies DB16-1, DB20-6, DB29-1, and DB41-2). The B-cell epitopes of DB20-6 and DB29-1 were identified by phage display and site-directed mutagenesis, and its binding motif, WXXWGK, was revealed to correspond to amino acid residues 115-120 of the DENV-2 NS1 protein. A diagnostic platform, consisting of a serotype-specific capture antibody and a complex detection antibody, exhibited a detection limit of about 1 ng/mL, which is sufficient to detect NS1 in clinical serum samples from dengue patients. This diagnostic platform displayed better specificity and sensitivity than two examined commercial NS1 diagnostic platforms. In summary, our results indicate that these newly generated mAbs are suitable for detection of NS1 protein of DENV-2 in clinical samples.
登革病毒(DENV)在全球热带和亚热带地区传播,在这些地区它会导致高发病率和死亡率。目前尚无有效的感染治疗方法,支持性护理是唯一的选择。此外,早期检测和诊断对于促进临床决策很重要。在本研究中,通过杂交瘤技术产生了七种识别登革病毒非结构蛋白1(NS1)的单克隆抗体(mAb)。这些抗体可分为两组:血清型特异性(DB6-1、DB12-3和DB38-1)和非特异性(由抗体DB16-1、DB20-6、DB29-1和DB41-2组成)。通过噬菌体展示和定点诱变鉴定了DB20-6和DB29-1 的B细胞表位,其结合基序WXXWGK被揭示对应于登革病毒2型NS1蛋白的115-120位氨基酸残基。一个由血清型特异性捕获抗体和复合检测抗体组成的诊断平台,其检测限约为1 ng/mL,足以检测登革热患者临床血清样本中的NS1。该诊断平台显示出比两个检测的商业NS1诊断平台更好的特异性和灵敏度。总之,我们的结果表明,这些新产生的单克隆抗体适用于检测临床样本中登革病毒2型的NS1蛋白。